The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Description

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

Conditions

Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Condition
Patients Undergoing Routine Health Care
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago Medical Center, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
  • * Life expectancy of at least 3 years
  • * Must be 18 years or older
  • * Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
  • * Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
  • * Patients requiring specialized cardiology care
  • * Patients with inflammatory bowel diseases
  • * Patients with systemic autoimmune or inflammatory diseases
  • * Patients requiring long-term oral anticoagulation
  • * Patients with hepatitis C
  • * Patients with non-metastatic cancer
  • * Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
  • * Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
  • * Inability to understand and give informed consent to participate.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Chicago,

Peter H O'Donnell, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2027-12-14